$1.25
1.63% yesterday
Nasdaq, Aug 11, 10:00 pm CET
ISIN
US17322U2078
Symbol
CTXR

Citius Pharmaceuticals Inc Target price 2025 - Analyst rating & recommendation

Citius Pharmaceuticals Inc Classifications & Recommendation:

Buy
78%
Hold
22%

Citius Pharmaceuticals Inc Price Target

Target Price $5.10
Price $1.25
Potential
Number of Estimates 4
4 Analysts have issued a price target Citius Pharmaceuticals Inc 2026 . The average Citius Pharmaceuticals Inc target price is $5.10. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 7 Analysts recommend Citius Pharmaceuticals Inc to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Citius Pharmaceuticals Inc stock has an average upside potential 2026 of . Most analysts recommend the Citius Pharmaceuticals Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Sep '24 2025
Estimates
Earnings Per Share $ -5.97 -3.33
7.18% 44.22%
P/E negative
EV/Sales 0.87

5 Analysts have issued a Citius Pharmaceuticals Inc forecast for earnings per share. The average Citius Pharmaceuticals Inc EPS is

$-3.33
Unlock
. This is
33.67% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-3.42 31.87%
Unlock
, the lowest is
$-3.19 36.45%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-5.97 7.18%
2025
$-3.33 44.22%
Unlock
2026
$1.39 141.74%
Unlock
2027
$3.09 122.30%
Unlock
2028
$2.79 9.71%
Unlock
2029
$3.18 13.98%
Unlock
2030
$3.33 4.72%
Unlock
2031
$3.62 8.71%
Unlock
2032
$3.75 3.59%
Unlock

P/E ratio

Current -0.25 92.71%
2025
-0.38 52.61%
Unlock
2026
0.90 336.84%
Unlock
2027
0.40 55.56%
Unlock
2028
0.45 12.50%
Unlock
2029
0.39 13.33%
Unlock
2030
0.38 2.56%
Unlock
2031
0.35 7.89%
Unlock
2032
0.33 5.71%
Unlock

Current Citius Pharmaceuticals Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
D. Boral Capital
Locked
Locked
Locked Jun 30 2025
D. Boral Capital
Locked
Locked
Locked Jun 10 2025
D. Boral Capital
Locked
Locked
Locked Jun 09 2025
Maxim Group
Locked
Locked
Locked May 23 2025
D. Boral Capital
Locked
Locked
Locked May 15 2025
D. Boral Capital
Locked
Locked
Locked Feb 18 2025
D. Boral Capital
Locked
Locked
Locked Jan 07 2025
Analyst Rating Date
Locked
D. Boral Capital:
Locked
Locked
Jun 30 2025
Locked
D. Boral Capital:
Locked
Locked
Jun 10 2025
Locked
D. Boral Capital:
Locked
Locked
Jun 09 2025
Locked
Maxim Group:
Locked
Locked
May 23 2025
Locked
D. Boral Capital:
Locked
Locked
May 15 2025
Locked
D. Boral Capital:
Locked
Locked
Feb 18 2025
Locked
D. Boral Capital:
Locked
Locked
Jan 07 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today